Signature Diagnostics Presents Positive Colorectal Screening Study Results
André Rosenthal, founder and CEO of Signature Diagnostics, cited the test's significance in fulfilling a large unmet clinical need: "Detector C is the safest and most accurate blood -based screening test available, making it particularly well suited for population screening. It has the potential to provide an early warning to hundreds of thousands of individuals with early stage colorectal cancer, enabling them to begin treatment while their disease is still curable."
Signature Diagnostics plans to launch Detector C by the end of this year.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.